The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
 
 
Employment - Amgen
Stock and Other Ownership Interests - Amgen
Cost effectiveness (CE) of blinatumomab (BLIN) versus inotuzumab ozogamicin (INO) in adult patients with relapsed/refractory (R/R) acute lymphoblastic leukemia (ALL) with no more than one prior salvage therapy (S0/S1) from a United Kingdom health care perspective.
 
Thomas E. Delea
Consulting or Advisory Role - Novartis (Inst)
Research Funding - 21st Century Oncology (Inst); Abbvie (Inst); Amgen (Inst); ARIAD (Inst); EMD Serono (Inst); GlaxoSmithKline (Inst); Jazz Pharmaceuticals (Inst); Lilly (Inst); Merck (Inst); Merck (Inst); Novartis (Inst); Pfizer (Inst); Sanofi (Inst); Seagen (Inst); Takeda (Inst); Vertex (Inst)
 
Xinke Zhang
Employment - Amgen
Stock and Other Ownership Interests - Amgen
 
Jordan Amdahl
Consulting or Advisory Role - Amgen (Inst)
Research Funding - Amgen (Inst)
Travel, Accommodations, Expenses - Novartis
 
Diana Boyko
Consulting or Advisory Role - Amgen; Amgen (Inst); Pfizer; Pfizer (Inst); Regeneron; Regeneron (Inst); Sanofi; Sanofi (Inst)
Research Funding - Amgen; Amgen (Inst); Pfizer; Pfizer (Inst); Regeneron; Regeneron (Inst); Sanofi; Sanofi (Inst)
 
Franziska Severin
Employment - Amgen
Stock and Other Ownership Interests - Amgen
 
Marco Campioni
Employment - Amgen
Stock and Other Ownership Interests - Amgen
 
Ze Cong
No Relationships to Disclose